China’s regulatory agency has granted priority review status to BeiGene‘s new drug application (NDA) requesting the approval of pamiparib, its investigational PARP inhibitor, for the treatment of advanced ovarian cancers. Priority review is granted in China to reduce the time to review and approve promising therapies that address urgent clinical needs. The NDA specifically covers patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more lines of chemotherapy and carry mutations in the…
You must be logged in to read/download the full post.
The post Pamiparib Granted Priority Review in China for Treatment of Advanced Ovarian Cancer appeared first on BioNewsFeeds.